NDC 55513-207

MVASI

Bevacizumab-awwb

MVASI is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Amgen Inc. The primary component is Bevacizumab.

• Product ID: 55513-207_35f7caed-b075-48fc-ac6d-4c1096124a51
• NDC: 55513-207
• Product Type: Human Prescription Drug
• Proprietary Name: MVASI
• Generic Name: Bevacizumab-awwb
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2018-06-01
• Marketing Category: BLA / BLA
• Application Number: BLA761028
• Labeler Name: Amgen Inc
• Substance Name: BEVACIZUMAB
• Active Ingredient Strength: 400 mg/16mL
• Pharm Classes: Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 55513-207-01

1 VIAL in 1 CARTON (55513-207-01) > 16 mL in 1 VIAL

• Marketing Start Date: 2018-06-01
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 55513-207-01 [55513020701]

MVASI INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA761028
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2018-06-01

Drug Details

Active Ingredients

Ingredient	Strength
BEVACIZUMAB-AWWB	400 mg/16mL

OpenFDA Data

• SPL SET ID: 0a562b4e-67ce-4bab-852c-d9ee71e55fb8
• Manufacturer:
  • Amgen Inc
• UNII:
  • 2S9ZZM9Q9V
• RxNorm Concept Unique ID - RxCUI:
  • 2046145
  • 2046148
  • 2046140
  • 2046149

Pharmacological Class

• Vascular Endothelial Growth Factor Inhibitor [EPC]
• Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
• Vascular Endothelial Growth Factor Inhibitors [MoA]

NDC Crossover Matching brand name "MVASI" or generic name "Bevacizumab-awwb"

NDC	Brand Name	Generic Name
55513-206	MVASI	bevacizumab-awwb
55513-207	MVASI	bevacizumab-awwb